{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:31:46Z","timestamp":1786692706987,"version":"build-2736575974"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:p>Mutant KRAS inhibition has revolutionized the treatment of lung adenocarcinoma. Unfortunately, responses to this form of targeted therapy are often of limited duration because of the development of resistance. Targeted protein degradation, including using PROTACs (PROteolysis-TArgeting Chimeras), presents an alternative approach to targeting oncogenic drivers in cancer. In this issue of Cancer Research, Mart\u00edn and colleagues developed a dTAG-KRASG12V syngeneic mouse model that allows for the study of the effects of degrading the KRASG12V oncoprotein in vivo. The authors discovered that degrading the KRASG12V oncoprotein leads to regression of the resulting lung adenocarcinoma tumors. Most of the regression was based on cancer cell\u2013intrinsic responses, although the tumor microenvironment also underwent substantial remodeling. Despite the initial efficacy of the treatment, the authors found that prolonged PROTAC KRAS degrader treatment eventually resulted in relapse. Resistance to PROTAC treatment seemed to be driven by dysregulation of the ubiquitin\u2013proteasome system that is required for the activity of the PROTAC degraders. Despite developing resistance to the PROTAC degraders, the resulting tumors were still dependent on the KRAS oncoprotein, meaning that they were still sensitive to conventional KRAS inhibitors. Thus, PROTACs that degrade the KRAS oncoprotein are a promising modality for the treatment of lung adenocarcinomas. Resistance to PROTACs may differ from conventional KRAS inhibitors, suggesting potential strategies for overcoming such resistance.<\/jats:p>\n                  <jats:p>See related article by Mart\u00edn et al., p. 4115<\/jats:p>","DOI":"10.1158\/0008-5472.can-26-2186","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:07:47Z","timestamp":1786691267000},"page":"3903-3905","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-6002","authenticated-orcid":false,"given":"Santiago","family":"Garcia Borrego","sequence":"first","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6031-0137","authenticated-orcid":false,"given":"Sandra","family":"Misale","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026081403074070500_bib1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2026081403074070500_bib2","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081403074070500_bib3","doi-asserted-by":"crossref","first-page":"e164413","DOI":"10.1172\/JCI164413","article-title":"Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas","volume":"133","author":"Salm\u00f3n","year":"2023","journal-title":"J Clin Invest"},{"key":"2026081403074070500_bib4","first-page":"254","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun Chem Nat Res"},{"key":"2026081403074070500_bib5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer","volume":"394","author":"Park","year":"2026","journal-title":"N Engl J Med"},{"key":"2026081403074070500_bib6","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"2026081403074070500_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2026081403074070500_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"key":"2026081403074070500_bib9","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1158\/0008-5472.CAN-25-5172","article-title":"Targeted KRASG12V degradation in vivo elicits lung adenocarcinoma regression with subsequent relapse from dysregulated proteolysis","volume":"86","author":"Mart\u00edn","year":"2026","journal-title":"Cancer Res"},{"key":"2026081403074070500_bib10","doi-asserted-by":"crossref","first-page":"e174249","DOI":"10.1172\/JCI174249","article-title":"Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models","volume":"135","author":"Li","year":"2024","journal-title":"J Clin Invest"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/16\/3903\/3819372\/can-26-2186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/16\/3903\/3819372\/can-26-2186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:07:49Z","timestamp":1786691269000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/16\/3903\/787292\/KRASG12V-Degraders-Provide-a-Potential-Therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":10,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,8,14]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-26-2186","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}